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Aim: To evaluate the new Octavius 4D system for patient speciﬁc quality assurance and to
study  the correlation between plan complexity and gamma index analysis in patient speciﬁc
quality assurance of VMAT using the Octavius 4D system.
Background: McNiven (2010) proposed a study to evaluate the utility of a complexity metric,
the  Modulation Complexity Score, to evaluate the relationship of the metric with deliver-
ability in IMRT.
Materials and methods: Evaluation of the Octavius 4D system was carried out by gamma
evaluation of user deﬁned MLC created patterns and AAPM TG 119 benchmark plans. The
relationship between plan complexity expressed as Modulation Complexity Score (MCS) and
the  gamma index analysis was established by a planar and volumetric gamma analysis of
106  clinically approved VMAT patient plans of different sites.
Results: Average volumetric 3D global gamma evaluation (3 mm/3%) results for the evaluation
plans  was 97.41% for 6 MV X-rays and 98.30% for 15 MV X-rays. Average MCS  values for the
head and neck, pelvic and thoracic plans were 0.2224, 0.3615 and 0.1874. Average volumetric
3D  global gamma analysis (3 mm/3%) results for the head and neck, pelvic and thoracic VMAT
plans  were 95.45%, 97.51% and 96.98%, respectively. Out of 90 correlation analyses between
the  MCS and gamma passing rate, only 3 had the r value greater than 0.5.Conclusions: The Octavius 4D system is a suitable device for patient speciﬁc pretreatment
QA. Global and local gamma analysis results showed a weak correlation with the MCS.
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1.  Background
Radiation therapy has long been recognized as an effective
method for treating cancer. Aim of radiotherapy is to deliver
uniform maximum dose of ionizing radiation to target vol-
ume  while minimizing dose to the critical organs and healthy
tissues. New treatment techniques, such as intensity mod-
ulated radiation therapy (IMRT) and volumetric modulated
arc therapy (VMAT), have enabled the escalation of target
dose with fewer side effects to the surrounding organs-at-risk.
Both IMRT  and VMAT  use intensity modulation to achieve the
desired dose distribution. In IMRT,  this is achieved by moving
multi-leaf collimators (MLC) during the course of treatment,
thereby delivering a radiation ﬁeld with a non-uniform inten-
sity. VMAT  delivers radiation by rotating the gantry through
one or more  arcs with radiation continuously on. In VMAT,
the number of parameters can be varied to achieve intensity
modulation volumetrically. These include: (i) the MLC  aper-
ture shape, (ii) the ﬂuence-output rate (“dose rate”) and (iii) the
gantry rotation speed. This increased complexity of clinical
treatments raises the need for more  accurate dose veriﬁcation
systems and procedures.1–3
Traditional pretreatment veriﬁcation involves point dose
measurements using ionization chambers and ﬂuence mea-
surements using ﬁlms or 2D array detectors. The process
usually involves the preparation of a veriﬁcation plan in the
treatment planning system (TPS) using the beam parame-
ters the same as those of the patient plan and delivered in
the phantom. Measured dose plane in the phantom is then
compared against the calculated dose using gamma  evalu-
ation ﬁrst introduced by Low et al.4 Various detectors have
been studied for IMRT  and VMAT  patient speciﬁc quality
assurance.5–9 Technological advancements have led to the use
of new 3D dosimeters and metrics for patient speciﬁc QA. Such
3D gamma metric extends analysis into a third-dimensional
axis, thereby providing full volumetric gamma  assessment as
an alternative to a single plane 2D gamma analysis. Octavius
4D system (PTW, Germany) is one such device that can per-
form 3D gamma evaluation. Stathakis et al.10 and McGarry
et al.11 performed characterization of the Octavius 4D system
for patient speciﬁc quality assurance in VMAT  deliveries.
The agreement between planned and measured dose dis-
tribution may be affected by both the accuracy of the TPS
calculation and the delivery accuracy. Quantiﬁcation of these
two causes of errors is a difﬁcult task. However, an analysis
based on plan parameters may provide important informa-
tion regarding delivery accuracy. Generally, a high degree of
complexity for ﬁxed-beam IMRT  has been associated with
multiple parameters (large number of MUs, complex segment
shapes, small segment apertures, large number of segments).
McNiven et al.12 proposed a single complexity metric (Mod-
ulation Complexity Score) for step-and-shoot IMRT plans. In
that study McNiven et al.12 stated the average MCS value
of 0.356 for head and neck IMRT.  McNiven et al.12 reported
no correlation between the IMRT  gamma passing rates and
the complexity metric, MCS  across multiple treatment sites.
Masi et al.13 proposed a study on the impact of plan parame-
ters in VMAT  dosimetric accuracy. In that study, Masi et al.13
stated the average MCS  value of 0.41 ± 0.11 ranged from 0.65diotherapy 2 0 ( 2 0 1 5 ) 57–65
to 0.19 for analyzed sites and correlated the complexity of the
plan with the planar gamma analysis passing rate. The cre-
ation of complexity metrics could provide a valuable tool for
improving plan optimization and veriﬁcation. Reduction of the
quality assurance workload can be accomplished by knowing
the complexity of the plan.
2.  Aim
This work consists of two parts, one is to evaluate the Octavius
4D system for patient speciﬁc quality assurance and the other
is to establish a correlation between plan complexity and the
gamma analysis passing rate for the VMAT plans using the
Octavius 4D system. Evaluation of the Octavius 4D system
was performed by comparing the planned and measured dis-
tribution of three MLC created distributions (PATTERNS) and
AAPM TG 11914 benchmark plans for IMRT and VMAT  using 3D
gamma evaluation. Based on McNiven et al.12 formalism, 106
clinically approved VMAT plans Modulation Complexity Score
(MCS) were determined and correlation between the MCS  and
gamma  passing rates (planar and volumetric) were obtained
using Pearson’s correlation coefﬁcient (r).
3.  Materials  and  methods
3.1.  Octavius  4D  system
Octavius 4D system is an independent QA tool for pretreat-
ment veriﬁcation of radiotherapy treatment plans. Its basic
components are: the Octavius Detector 729, the Octavius Rota-
tion unit, Inclinometer, Control Units and Verisoft (V.5.1). The
radiation detector used in this study was the PTW Octavius
Detector 729TM (PTW, Freiburg, Germany). The Octavius detec-
tor array comprises 729 air-vented cubic ionization chambers
uniformly arranged in 27 × 27 matrices with an active area
of 27 cm × 27 cm.  The ionization chambers in the detector
array are arranged in such a manner that the center-to-center
distance is 1 cm and the edge-to-edge distance is 0.5 cm.
Each detector size is 0.5 cm × 0.5 cm × 0.5 cm (0.125 cm3) with
effective point of measurement located at 0.75 cm below the
surface of the array. It has dead time free read-out and the
arrays operate at chamber voltage of +1000 V. The detector
array is mounted in an Octavius rotation unit, which is a
motorized cylindrical phantom with a diameter of 32.0 cm
and length of 34.3 cm.  The built-in mechanics and the motor
allow the cylinder to rotate, ensuring perpendicular inci-
dence of the radiation beam on the detector array at all
times. The rotation unit is made up of polystyrene mate-
rial and has a density of 1.05 g/cm3. Inclinometer attached
to the vertical part of the gantry measures the gantry angles,
and allows the dose measurement as a function of time (or)
gantry angle. Its measurement range is 360◦ rotation. The
motorized Octavius rotation unit rotates synchronously with
the gantry by reading inclinometer’s output. The Octavius
detector, which always remains aligned perpendicular to the
incident beam, measures the dose plane for each gantry angle.
The dose measurements together with the corresponding
inclinometer data were transferred to a personal computer for
data analysis.
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The gamma analyses were done with the Octavius 4D sys-
em accomplishing software Verisoft (V.5.1). The measured
ose planes for each gantry angle were used to reconstruct
he dose values in the phantom volumetrically by applying
 proprietary algorithm developed by DKFZ Heidelberg based
n PDD curves measured for various ﬁeld sizes ranging from
 cm × 4 cm to 26 cm × 26 cm for the accelerator and energy in
se. All the dose points (measured and extrapolated using PDD
urves) at a given gantry angle were summed over all gantry
ngles to create a volumetric dose distribution with a user-
electable resolution of typically 2.5 mm.  Those reconstructed
easured dose cubes were compared against the calculated
ICOMRT dose cubes, at any particular plane or whole volume.
hroughout this study, planar dose analyses were done in the
agittal and coronal planes passing through the isocenter.
.2.  Evaluation  of  the  Octavius  4D  system
hree different MLC  created patterns were planned in Varian
clipse treatment planning system (Varian Medical Systems,
alo Alto, US) using AcurosXB 11.0.21 calculation algorithm
or Varian CLINAC 2100 C/D (Varian Medical Systems, Palo
lto, US) having 6 MV and 15 MV  X-rays equipped with millen-
ium 120 MLC. Measurements were done for both 6 MV and
5 MV X-rays in the Octavius 4D system to evaluate its per-
ormance toward MLC  produced patterns. Pattern I consists
f ﬁve bands in the vertical axis (Y axis), 3 cm wide, with the
LC  transmission factor from 0.2 to 1.0. Pattern II is a reverse
yramid structure consisting of six steps, with the MLC trans-
ission factor from 1.2 (at edge) to 0.2 (at center). Pattern III is a
yramid structure consisting of six steps, with the MLC trans-
ission factor from 0.2 (at edge) to 1.2 (at center). The entire
D distributions were analyzed using global gamma  criteria
f 3 mm/3% with a 10% threshold. All the dosimetric mea-
urements in this study were carried out by positioning the
socenter at the central ion chamber (14, 14) effective point of
easurement. The standard setup of the Octavius 4D systemn the treatment room is shown in Fig. 1.
AAPM Task Group (TG) 11914 guidelines have established
tandard test plans consisting of simpliﬁed target structures
ig. 1 – Standard measurement setup of the Octavius 4D
ystem.iotherapy 2 0 ( 2 0 1 5 ) 57–65 59
along with organs at risk (OAR) and planning goals to bench-
mark the overall accuracy of IMRT planning and delivery.
AAPM TG 11914 recommends four benchmark plans, namely
multi-target, mock  prostate, mock  head and neck and C-shape
for commissioning of IMRT.  To evaluate the performance of
the Octavius 4D system AAPM TG 119 benchmark plans were
utilized in this study. Each plan uses contours of targets and
avoidance structures drawn within the 4D phantom in the TPS.
Both IMRT and VMAT plans were generated in accordance to
the planning objectives stated in AAPM TG 119.14 These test
plans were delivered in the Octavius phantom and dosimet-
ric comparisons have been made between TPS calculated and
measured dose distribution for 3 mm/3% global gamma crite-
ria with a 10% threshold.
3.3.  Correlation  between  the  plan  complexity  and  the
gamma  passing  rate
McNiven et al.12 proposed a study to evaluate the utility of
a complexity metric, the MCS in quality assurance to evalu-
ate the relationship of the metric with deliverability in IMRT.
MCS calculation is based on three parameters: segment shape,
area and weight. The parameter leaf sequence variability (LSV)
was used to characterize the variation in segment shape and
parameter aperture area variability (AAV) was used to charac-
terize the variation in segment area relative to the maximum
aperture deﬁned by all the segments. The relative segment
weight was also incorporated into the ﬁnal complexity score.
The MCS for a plan is the product of LSV and AAV weighted
by the relative MU. The MCS, as in the original deﬁnition,
has the value range from 0 to 1. MCS = 1 means no modula-
tion and the average MCS score for a treatment site always
decreases with increased inherent complexity. Recently, based
on McNiven et al.12 formalism, Masi et al.13 investigated the
impact of a plan parameter on the dosimetric accuracy (pla-
nar gamma analysis passing rate) of VMAT.  As part of our
work, we developed a MATLAB program to compute the MCS
score for VMAT plans. All VMAT plans were exported and con-
verted from DICOM to ASCII format. For each arc ﬁeld, the
exported plan contains information about (i) jaws  position, (ii)
number of control points, (iii) MLC leaf positions for each con-
trol point, (iv) cumulative MU weights for each control point
and (v) MU for each arc ﬁeld. This information was extracted
using an in-house developed Excel spreadsheet (Microsoft Cor-
poration, US) to MATLAB. Based on the formalism given by
McNiven et al.12 and Masi et al.,13 MCS and its parameters for
each VMAT plans were determined in MATLAB by following
formulae:
posmax(CP) = 〈max(posn ∈ N) − min(posn ∈ N)〉MLC bank
where pos is the coordinate of the leaf position and N is the
number of moving leaves inside the jaw position.
LSVCP =
〈∑N−1
n=1 (posmax − |(posn − posn+1)|)
(N − 1) × posmax
〉
left bank〈 〉×
∑N−1
n=1 (posmax − |(posn − posn+1)|)
(N − 1) × posmax
right bank
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AAVCP
=
∑A
a=1(〈posa〉left bank − 〈posa〉right bank)∑A
a=1(〈max(posa)〉left bank ∈ arc − 〈max(posa)〉right bank ∈ arc)
where A is the number of leaves in the arc.
MCSarc =
I−1∑
i=1
[
AAVCPi + AAVCPi+1
2
×
LSVCPi + LSVCPi+1
2
×
MUCPi,i+1
MUarc
]
where MUCPi,i+1 represents the MU  delivered between two suc-
cessive control points and I represent the total number of
control points.
MCSplan =
J∑
j=1
MCSarcj ×
MUarcj
MUplan
where J is the number of arcs in the plan.
Different clinical treatment sites have an inherent differ-
ence in the level of complexity that would be required to
create a clinically acceptable plan, based on the differences
in a target shape, size, and location with respect to criti-
cal structures. For this purpose, three different sites (head
and neck, thoracic and pelvic) were chosen for this study. To
establish the relation between the plan complexity and the
gamma passing rate, 106 clinically approved VMAT  treatment
plans were used in this study. These 106 plans consist of 36
head and neck site, 35 thoracic site (esophagus) and 35 pelvic
site (cervix) plans. All the VMAT  plans were optimized for
6 MV  X-rays double arc using Varian Eclipse treatment plan-
ning system v.11.0 (Varian Medical Systems, Palo Alto, US)
to meet the clinical requirements. Dose calculation for all
the VMAT  plans was performed using the AcurosXB 11.0.21
algorithm. Measurements were carried out for each VMAT
plan in the Octavius 4D system and dosimetric evaluation
between planned (AcurosXB 11.0.21) and measured distribu-
tion was done using the Verisoft (V5.1). Measured dose values
were corrected for daily linac output variation. In this study,
we  performed the gamma evaluation in two different analy-
sis methods, global (maximum dose normalization) and local
(dose at the corresponding position of the reference matrix
normalization) gamma analysis. In this study, we evaluated
the gamma (global and local gamma analysis) with three dif-
ferent criteria 3 mm/3%, 2 mm/2% and 1 mm/1%, all of them
with a 10% threshold. Correlation between the plan complex-
ity (MCS) and the gamma analysis passing rate was examined
Table 1 – Global gamma  evaluation (3 mm/3%) results for user d
Energy Pattern 
Planar a
2D 
Coronal Sagittal 
6 MV
Pattern I 95.1 95.8 
Pattern II 95.2 95.1 
Pattern III 100.0 99.9 
15 MV
Pattern I 99.4 99.8 
Pattern II 95.1 97.3 
Pattern III 97.0 100.0 diotherapy 2 0 ( 2 0 1 5 ) 57–65
using Pearson’s correlation coefﬁcient (r). Correlation was con-
sidered weak for r < 0.5, moderate for 0.5 ≤ r ≤ 0.75 and strong
for r > 0.75.
4.  Results
4.1.  Evaluation  of  the  Octavius  4D  system
Planar and volumetric 3D global gamma evaluation (3 mm/3%
with 10% threshold) results for the user deﬁned MLC  created
patterns are shown in Table 1 for 6 MV and 15 MV X-rays. Pla-
nar and volumetric gamma evaluation (3 mm/3%) results of
the AAPM TG 119 test cases for IMRT and VMAT are shown
in Tables 2 and 3, respectively. For 3 mm/3% global gamma
criteria, both the user deﬁned MLC created patterns and
AAPM TG-11914 plans had a gamma index passing rate higher
than 95%. 3D gamma analysis passing rate for a speciﬁc test
resulted in a slightly higher passing rate than the 2D gamma
analysis passing rate. Average volumetric 3D global gamma
evaluation (3 mm/3%) passing rates for the user deﬁned pat-
terns were 97.63% for 6 MV X-rays and 99.23% for 15 MV X-rays.
AAPM TG-11914 benchmark IMRT and VMAT  plans average vol-
umetric 3D global gamma evaluation (3 mm/3%) passing rates
were 97.08% and 97.58% for 6 MV X-rays. For 15 MV  X-rays, the
average volumetric 3D global gamma  evaluation (3 mm/3%)
results were 98.50% and 97.40%. Volumetric 3D gamma pass-
ing rate for the evaluated plans ranged from 96.1% to 98.4% for
6 MV  X-rays and from 95.6% to 99.9% for 15 MV X-rays.
A good quality assurance tool is the one that is easy to
understand and implement in the clinical process which can
provide useful information. In this work, dosimetric evalu-
ation of the Octavius 4D system was carried out for MLC
modulated beams and AAPM TG 11914 benchmark plans. Even
though the detector centers are spaced 1 cm apart, the algo-
rithm is able to satisfactorily reconstruct the doses with the
resolution of 0.25 cm,  all over the volume and the same can be
inferred from the results. The 3D dose reconstruction in the
phantom allows the user to select any plane (axial, coronal
and sagittal) for the evaluation. Moreover, a 3D gamma index
can be calculated, which expands the search radius for the
gamma index to include the dose planes adjacent to the one
that is evaluated. In addition, a volumetric 3D gamma index
can be calculated which measures the gamma index for each
voxel in the entire phantom volume. With the use of Octavius
eﬁned MLC  created ﬂuence pattern.
Gamma  passing rates (%)
nalysis Volumetric analysis
3D
Coronal Sagittal
95.2 96.9 96.6
95.3 95.2 97.9
100.0 99.9 98.4
99.5 99.8 99.8
95.7 97.3 98.0
97.6 100.0 99.9
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Table 2 – Global gamma  evaluation (3 mm/3%) results of AAPM TG 119 benchmark IMRT  plans.
Energy Benchmark plans Gamma  passing rates (%)
Planar analysis Volumetric analysis
2D 3D
Coronal Sagittal Coronal Sagittal
6 MV
Multi-target 96.8 98.1 97.0 98.1 96.7
Prostate 95.2 95.6 96.9 95.1 97.9
Head and neck 95.4 95.8 95.6 95.3 96.1
C-shape 95.6 97.3 97.0 97.4 97.6
15 MV
Multi-target 98.5 98.6 98.5 98.6 99.7
Prostate 95.8 95.6 95.4 95.5 98.7
Head and neck 95.2 96.9 95.5 97.2 98.1
C-shape 96.9 96.8 97.1 96.9 97.4
Table 3 – Global gamma  evaluation (3 mm/3%) results of AAPM TG 119 benchmark VMAT  plans.
Energy Benchmark plans Gamma  passing rates (%)
Planar analysis Volumetric analysis
2D 3D
Coronal Sagittal Coronal Sagittal
6 MV
Multi-target 95.7 96.3 95.9 96.4 98.3
Prostate 95.1 95.8 95.5 95.8 97.6
Head and neck 96.4 95.6 96.8  96.3 96.1
C-shape 97.8 97.3  97.9 97.5 98.3
Multi-target 95.8 97.4 95.9 97.8 97.9
5.6 96.0 95.7 95.6
5.6 96.4 96.3 97.9
6.9 95.8 97.1 98.3
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Fig. 2 – Graphical representation of volumetric global
gamma  evaluation (3 mm and 3%) results for all the 10615 MV
Prostate 95.6 9
Head and neck 96.0 9
C-shape 95.5 9
D system, it is possible to compare and analyze the volumet-
ic dose ﬁeld by ﬁeld for IMRT  or control point by control point
or VMAT  in a single measurement. Potential improvements
n the device could be achieved with closer detector spacing
or better resolution.
.2.  Correlation  between  the  plan  complexity  and  the
amma  passing  rate
able 4 shows the dosimetric evaluation results of 106 clini-
ally approved VMAT  plans for both global and local gamma
valuation. It shows the mean 2D and 3D planar gamma eval-
ation results in the sagittal and coronal plane, as well as
olumetric 3D gamma evaluation with their corresponding
tandard deviations. Fig. 2 represents the volumetric 3D global
amma evaluation results graphically for 3 mm/3% criteria
ith a 10% threshold. Average volumetric 3D global gamma
nalysis (3 mm/3%) results in the head and neck, pelvic and
horacic VMAT  plans were 95.45%, 97.51% and 96.98%, whereas
or all the analyzed plans (106), the average volumetric 3D
lobal gamma analysis (3 mm/3%) result was 96.63% ± 1.53%.
he number of voxels that met  the 3 mm/3% global gamma
riteria for the volumetric 3D gamma index analysis ranged
rom 92.4% to 99.3%. Average 2D planar (coronal and sagi-
tal) gamma analysis passing rate was 95.31% ± 1.68% ranging
rom 88.9% to 99.0%. Average 3D planar (coronal and sagittal)
amma analysis passing rate was 96.06% ± 1.39% ranging from
2.0% to 99.3%. For all the plans, the 3D planar gamma  analysisVMAT  patients plan.
passing rate resulted in a higher passing rate than that of
2D, as expected. Applying stringent criteria, like 2 mm/2%
and 1 mm/1%, resulted in a lower passing rate for all 2D
and 3D gamma analysis methods, as expected. Among the
three sites, thoracic site resulted in a higher passing rate,
whereas head and neck site resulted in a lower passing rate
for global gamma analysis. Local gamma  analysis method
always resulted in a lower passing rate than the global gamma
62  reports of practical oncology and radiotherapy 2 0 ( 2 0 1 5 ) 57–65
Table 4 – Average gamma  evaluation passing rate of VMAT  QA plans with their corresponding standard deviation.
Gamma  criteria Site Gamma  passing rates (%)
Planar analysis Volumetric analysis
2D 3D
Coronal Sagittal Coronal Sagittal
Global 3 mm/3%
Head and neck 95.28 ± 1.10 95.12 ± 1.44 95.94 ± 1.09 95.63 ± 1.30 95.45 ± 1.15
Thoracic 95.77 ± 1.39 95.73 ± 2.10 96.40 ± 1.26 96.38 ± 1.51 97.51 ± 1.28
Pelvic 95.48 ± 1.78 95.83 ± 1.48 96.05 ± 1.43 96.06 ± 1.41 96.98 ± 1.34
Global 2 mm/2%
Head and neck 83.04 ± 4.58 80.10 ± 4.41 84.96 ± 4.38 81.21 ± 4.34 83.01 ± 4.12
Thoracic 87.01 ± 3.11 84.33 ± 4.04 87.81 ± 2.97 85.23 ± 3.56 88.67 ± 1.91
Pelvic 78.61 ± 4.47 83.74 ± 4.12 82.00 ± 4.25 84.38 ± 3.98 83.98 ± 4.83
Global 1 mm/1%
Head and neck 52.14 ± 5.53 46.36 ± 5.37 54.06 ± 5.38 47.24 ± 5.33 49.71 ± 5.50
Thoracic 57.47 ± 4.42 50.83 ± 6.02 58.27 ± 4.33 51.47 ± 5.83 58.05 ± 3.03
Pelvic 44.38 ± 5.24 51.35 ± 6.88 47.08 ± 5.63 51.77 ± 6.91 50.65 ± 6.25
Local 3 mm/3%
Head and neck 89.15 ± 2.90 84.46 ± 2.97 91.56 ± 2.34 86.66 ± 2.83 88.18 ± 2.28
Thoracic 87.87 ± 2.66 85.67 ± 4.37 90.15 ± 2.38 87.95 ± 3.36 87.53 ± 2.94
Pelvic 83.73 ± 3.95 83.01 ± 3.23 88.39 ± 2.89 85.31 ± 2.92 85.33 ± 3.26
Local 2 mm/2%
Head and neck 71.51 ± 4.40 64.52 ± 4.74 75.31 ± 4.22 67.23 ± 4.71 69.13 ± 4.61
Thoracic 70.69 ± 3.76 66.50 ± 6.36 73.63 ± 3.64 69.24 ± 5.79 69.29 ± 4.83
Pelvic 64.56 ± 6.00 64.05 ± 4.11 70.55 ± 6.12 66.71 ± 3.77 66.03 ± 5.30
Head and neck 36.72 ± 3.76 30.53 ± 3.09 40.27 ± 3.92 32.60 ± 3.23 34.12 ± 3.56
94 ± 5
85 ± 4
thoracic and pelvic sites, respectively.
Table 6 shows correlation coefﬁcients (r) between the
MCS and gamma  passing rate. Results showed a maximumLocal 1 mm/1% Thoracic 37.03 ± 3.35 33.
Pelvic 31.22 ± 5.02 29.
analysis method regardless of evaluation criteria. Average vol-
umetric 3D local gamma  analysis passing rate of all the plans
was 85.57% ± 5.55%. Among the three sites, the thoracic site
resulted in a higher passing rate, whereas the pelvic site
resulted in a lower passing rate for local gamma analysis.
MCS  and its dependent parameters LSV and AAV with their
standard deviation and ranges are shown in Table 5. Among
the three sites, thoracic site resulted in a higher MCS value
and the pelvic site resulted in a lower MCS  value. Average MCS
values for the head and neck, thoracic and pelvic sites were
0.2224, 0.3615 and 0.1874, respectively. Average MCS value of
the pelvic site is higher than that of the head and neck site,
which is similar to the results of McNiven et al.12 study. Within
the speciﬁc site, MCS  of the thoracic site resulted in a higher
relative standard deviation (%RSD) of 14.25%, whereas for the
head and neck and pelvic sites these were 10.07% and 14.03%,
respectively. Average MCS  for the entire 106 plans was 0.2555
with %RSD of 30.92%. The MCS  analysis shows that there is no
drastic variation in the LSV value, but notable variation was
seen in the AAV value among the three sites. The reason for
the same can be attributed to the nature of the optimization
algorithm and to the nature of target and critical structures.
Average LSV and AAV value for those 106 plans were 0.7446
and 0.3301, respectively. Within the speciﬁc site, %RSD of LSV
for the head and neck, thoracic and pelvic sites were 2.89%,
3.29% and 3.74%, respectively. %RSD of AAV for the head and
neck, thoracic and pelvic sites were 10.87%, 13.64% and 11.12%,
respectively. Among 106 plans, %RSD of LSV was 3.85%, which
is approximate to the speciﬁc site. But among 106 plans, %RSD
of the AAV value was 27.29%, which is much greater than that
of the speciﬁc site. Among the three sites, the pelvic VMAT
plans showed a larger aperture area variation in compari-
son to the head and neck and thoracic sites. However, the.29 39.53 ± 3.42 35.87 ± 5.52 35.33 ± 4.00
.08 36.09 ± 5.75 31.94 ± 3.79 32.03 ± 4.33
global gamma  passing rate was lower for the head and neck
VMAT plans compared to the thoracic and pelvic VMAT  plans,
whereas the local gamma passing rate was low for the pelvic
plans. Both the LSV and AAV of a plan depend on the max-
imum adjacent leaf separation and maximum aperture area
of that plan. Figs. 3–5 represent the spread of the volumetric
3D gamma  passing rate (3 mm/3% criteria with 10% thresh-
old) against the MCS  value of the plan for the head and neck,Fig. 3 – Spread of volumetric 3D global gamma  passing rate
for 3 mm/3% criteria against head and neck site plans MCS.
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Table 5 – Average MCS  values with standard deviation (SD) and ranges determined using the in-house MATLAB program.
Site Parameter MCS LSV AAV
All sites
Mean  0.2555 0.7446 0.3301
SD 0.0790 0.0287 0.0900
Max 0.4060 0.8290 0.5152
Min 0.1356 0.6962 0.1897
Head and neck
Mean  0.2224 0.7373 0.3009
SD 0.0224 0.0213 0.0327
Max 0.2592 0.7919 0.3501
Min 0.1838 0.6962 0.2484
Thoracic
Mean 0.3615 0.8290 0.4422
SD 0.0515 0.0273 0.0603
Max 0.4060 0.7576 0.5152
Min 0.3029 0.7000 0.3122
Pelvic
Mean 0.1874 0.7299 0.2492
SD 0.0263 0.0273 0.0277
Max 0.2213 0.7916 0.2971
Min 0.1356 0.7055 0.1897
Fig. 4 – Spread of volumetric 3D global gamma  passing rate
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Fig. 5 – Spread of volumetric 3D global gamma  passing rate
or 3 mm/3% criteria against thoracic site plans MCS.
orrelation of 0.68 for 2 mm/2% global gamma criteria in
 sagittal plane 2D analysis. In the case of a volumetric
D analysis, maximum correlation was observed for the
horacic site global gamma analysis with 1 mm/1% gamma
riteria. Out of 90 correlation analyses between the MCS
nd gamma passing rate, only 3 had the r value greater
han 0.5; moreover, no trend was found in the correlation
esults. Beam complexity is not the single source contribut-
ng to the dose errors. Dose errors may arise from many
easurement errors, such as a partial volume effect of ion
hambers, uncertainty, MLC  leaf position error, dose rate
amp up/down error, gantry sag or wobble, neglected couch
ttenuation, etc. Errors in TPS beam modeling and MLC mod-
ling also contribute to the dose discrepancies between the
easured and calculated ones. Perhaps, a stronger correla-
ion between beam complexity and VMAT  deliverability can
e observed in a prospective study, in which the effect offor 3 mm/3% criteria against pelvic site plans MCS.
beam complexity is isolated from many  other sources of dose
errors.15 Even though it was observed that there is weak
correlation between gamma passing rates and plan com-
plexity (MCS), the analysis of many  clinical treatment plans
allows for the accumulation of treatment site and technique-
speciﬁc statistics. The standard deviation of the scores also
provides insight to the standardization of a technique. The
“typical” complexity score for a speciﬁc site could prove use-
ful during training, planning, plan selection, and physics
QA. With respect to training for treatment planning; the
statistics can help a planner in ﬁnding ways to potentially
improve the treatment plan and to understand the type of
complexity that is typically achievable. The ability to charac-
terize plan complexity with a simple measure such as MCS
could also aid in the decision making process. MCS  could
also play a role in the clinic for the purposes of plan selec-
tion where a lower MCS plan would be desirable among
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Table 6 – Correlation coefﬁcients (r) between MCS  and gamma  evaluation passing rate.
Gamma  criteria Site Planar analysis Volumetric analysis
2D 3D
Coronal Sagittal Coronal Sagittal
Global 3 mm/3%
Head  and neck 0.05 0.49 0.18 0.44 0.05
Thoracic 0.36 0.17 0.20 0.24 0.32
Pelvic 0.06 0.26 0.27 0.24 0.18
Global 2 mm/2%
Head  and neck 0.07 0.19 0.14 0.22 0.06
Thoracic 0.32 0.68 0.30 0.67 0.43
Pelvic 0.11 0.13 0.01 0.11 0.16
Global 1 mm/1%
Head  and neck 0.02 0.08 0.03 0.12 0.03
Thoracic 0.01 0.48 0.00 0.46 0.46
Pelvic 0.05 0.04 0.01 0.05 0.05
Local 3 mm/3%
Head  and neck 0.13 0.05 0.12 0.16 0.06
Thoracic 0.27 0.44 0.28 0.47 0.37
Pelvic 0.37 0.45 0.27 0.46 0.27
Local 2 mm/2%
Head  and neck 0.23 0.09 0.24 0.19 0.09
Thoracic 0.15 0.38 0.10 0.35 0.34
Pelvic 0.38 0.33 0.33 0.31 0.16
Head  and neck 0.45 0.25 0.42 0.34 0.26
0.2
0.5
rLocal 1 mm/1% Thoracic 0.11 
Pelvic 0.48 
similar plans in terms of target coverage and organ-at-risk
sparing.
5.  Conclusions
Based on evaluation results, we  conclude that the Octavius 4D
system is a suitable device for patient speciﬁc pretreatment
QA. The ability of the system to reconstruct the volumetric
dose distribution in the phantom provides additional infor-
mation when compared to the conventional 2D detectors
measurements. User deﬁned intensity patterns and AAPM
TG 11914 benchmark plans’ results conform its ability for the
quality assurance of intensity modulated beams. Correlation
results between the MCS  and gamma  analysis results indicate
that MCS  of a plan has a weak correlation with the planar as
well as volumetric gamma analysis passing rates. The MCS
allows for a quantitative assessment of plan complexity and
can provide more  information related to dose delivery than
simple beam parameters such as monitor units. This could
prove useful throughout the entire treatment planning and
QA process. Strong correlation between beam complexity and
the gamma passing rate may be observed in which the effect
of beam complexity is set apart from many  other sources of
dose errors.
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